NCT05656248 · OUTCOME

Tolerability Success Rate (TSR) for the First Course of Chemotherapy

Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms · Source last updated 2026-10-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: Adverse events will be monitored from the time of first study intervention or treatment until the completion of the first course of therapy

What was measured

We define a tolerability success as a patient completing the first course of therapy without experiencing a grade 4 or 5 non-hematologic toxicity.

Analysis population: Patients who completed the first cycle.

All eligible patients received the first cycle of CPX-351 for remission induction.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
CPX-351 (Vyxeos)	25

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
CPX-351 (Vyxeos)	24	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

denoms

description

We define a tolerability success as a patient completing the first course of therapy without experiencing a grade 4 or 5 non-hematologic toxicity.

groups

param Type

COUNT_OF_PARTICIPANTS

population Description

Patients who completed the first cycle.

reporting Status

POSTED

time Frame

Adverse events will be monitored from the time of first study intervention or treatment until the completion of the first course of therapy

title

Tolerability Success Rate (TSR) for the First Course of Chemotherapy

type

PRIMARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-d643ffaf417bcef6d45eb5e0

Preserved source evidence · Not medical advice